The company said Monday it was putting up walls among its businesses and will begin financial reports for each of them starting in January. The key: each has its own emerging markets business unit.
Business briefs: Onyx, Pfizer, Covidien
July 1, 2013
5:58 pm
Onyx says no to Amgen bid, yes to other options; Pfizer/BMS may be able to expand Eliquis appeal; Covidien officially divides into two.
The Pfizer chief told investors that the company will provide “transparency” on its new and established products businesses, with a view toward a possible Abbott-esque spinoff down the road